Related Experiment Video
Updated: Dec 28, 2025
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.4K
Prognostic Biomarkers for Melanoma Immunotherapy
Christopher G Twitty1, Laura A Huppert2, Adil I Daud3
1OncoSec Inc., 3565 General Atomics Ct, San Diego, CA, 92121, USA.
Current Oncology Reports
|February 13, 2020
Summary
Immunotherapy has revolutionized melanoma treatment by enabling the immune system to fight tumors. This review explores key biomarkers indicating patient response to these advanced therapies.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Immunotherapy has significantly advanced melanoma treatment.
- Current therapies target immune checkpoints to facilitate tumor rejection.
- Treatment efficacy relies on a pre-existing anti-tumor immune response.
Purpose of the Study:
- To review established and emerging biomarkers for predicting response to melanoma immunotherapy.
- To elucidate the complexities of the anti-tumor immune response in melanoma.
Main Methods:
- Review of current scientific literature on melanoma immunotherapy and biomarkers.
- Analysis of the mechanisms underlying anti-tumor immune responses.
- Examination of clinical and investigational biomarkers.
Main Results:
- Immunotherapies, such as checkpoint inhibitors, leverage the immune system against melanoma.
- The effectiveness of immunotherapy is linked to the patient's pre-existing immune status.
- Several biomarkers are currently used or under investigation to predict treatment outcomes.
Conclusions:
- Understanding the anti-tumor immune response is crucial for developing effective biomarkers.
- Biomarker development is key to personalizing melanoma immunotherapy.
- Advances in biomarker research promise improved therapeutic strategies for melanoma patients.
